Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT05406661

Registry of Local Recurrences After Breast-conserving Surgery — R_ReLoCC  

Breast Cancer Recurrent Clinical Trial

Official title:
Registry of Local Recurrences After Breast-conserving Surgery in Portugal and Spain

Clinical Trial Summary

The ReLoCC project is a prospective, multicenter, clinical study to register cases of local recurrence after breast-conserving surgery, in centers dedicated to the treatment of breast cancer, in Portugal and Spain. The comparison of the results obtained will allow the optimization of the treatment, making it increasingly personalized.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05406661
Study type Observational [Patient Registry]
Source Universidade do Porto
Contact Diana Gonçalves, MD, PhDc
Phone (+351) 913017481
Email diana.goncalves@chsj.min-saude.pt
Status Not yet recruiting
Phase
Start date December 1, 2023
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1
Recruiting NCT05592938 - Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) N/A
Completed NCT04330339 - Prolonged Nightly Fasting in Breast Cancer Survivors N/A
Active, not recruiting NCT02915445 - EpCAM CAR-T for Treatment of Advanced Solid Tumors Phase 1
Completed NCT02844335 - Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer Phase 1/Phase 2
Recruiting NCT05464082 - Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC Phase 2
Completed NCT05301010 - Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients Phase 3
Recruiting NCT05730608 - 18F-FDG PET/CT Imaging for Breast Cancer N/A
Completed NCT01552655 - Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT N/A
Recruiting NCT03820830 - Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Phase 3
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4
Recruiting NCT02947061 - S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer Phase 2